Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis
Xiao-Yu Zhou, Qi Wu, Hao-lan Lu, Jia-Jie Xie, Yu-Fan Zhang, Yong Xu, Man Guo, Fang-Yuan Teng · 2026
Read Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis by Xiao-Yu Zhou, Qi Wu, Hao-lan Lu, Jia-Jie Xie, Yu-Fan Zhang, Yong Xu, Man Guo, Fang-Yuan Teng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13523518.txt.
Description
Xiao-Yu Zhou and colleagues pool, in a 2026 systematic review and meta-analysis, cardiovascular outcomes for two diabetes drugs, semaglutide and tirzepatide, in adults living with type 2 diabetes, overweight, or obesity. Both drugs are widely used, yet heart outcome evidence differed in maturity. The reviewers searched six sources through November 2024.
Forty-seven randomized trials with 59,352 participants were included. Semaglutide was linked with lower risk of major adverse cardiovascular events, cardiovascular death, heart attack, and heart failure, while the stroke estimate fell short of statistical significance. Tirzepatide showed a lower heart attack risk, but its other cardiovascular estimates were not significant. Because most trials compared each drug with a control rather than head to head, the authors warn against reading the results as proof that one drug beats the other.
Catalog record
| CREATOR | Xiao-Yu Zhou, Qi Wu, Hao-lan Lu, Jia-Jie Xie, Yu-Fan Zhang, Yong Xu, Man Guo, Fang-Yuan Teng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44483 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |